The Rehab William Stilley: Working On New Alcohol Addiction Treatments At Adial Pharmaceuticals
May 19, 2022
41:45
Speaking with the CEO and founder of a pharmaceutical company was an incredible experience. William Stilley knows the science inside and out. And, he is able to explain it clearly, in understandable terms.
What makes Adial different from many of the well-known drug companies is that they are working on new molecules to target specific receptors very precisely, rather than simply repackaging old products, or selling drugs that recklessly go after many receptors, leading to more side effects and adverse reactions. Additionally, their treatment for alcohol use disorder is a drug that works best for people with a specific genetic profile.
It will be the first genetically targeted therapy available to the public. For patients who have a positive match on the prerequisite genetic screen, this treatment may be expected to work effectively, with minimal concern for side effects.
We also discussed another drug that is in early development that is being studied for use in treating pain. The mechanism involves increasing adenosine, which may be useful for many other conditions as well. Mr. Stilley described it as being like caffeine times 200, but without the adverse effects of caffeine.
I look forward to seeing the results of this upcoming research and the possibilities for new treatments in the Adial pipeline. Thank you to William Stilley for joining me on the podcast.
If you enjoy this podcast episode, please subscribe. Also, please visit our practice website at https://drleeds.com and our podcast website: https://therehab.com.
What makes Adial different from many of the well-known drug companies is that they are working on new molecules to target specific receptors very precisely, rather than simply repackaging old products, or selling drugs that recklessly go after many receptors, leading to more side effects and adverse reactions. Additionally, their treatment for alcohol use disorder is a drug that works best for people with a specific genetic profile.
It will be the first genetically targeted therapy available to the public. For patients who have a positive match on the prerequisite genetic screen, this treatment may be expected to work effectively, with minimal concern for side effects.
We also discussed another drug that is in early development that is being studied for use in treating pain. The mechanism involves increasing adenosine, which may be useful for many other conditions as well. Mr. Stilley described it as being like caffeine times 200, but without the adverse effects of caffeine.
I look forward to seeing the results of this upcoming research and the possibilities for new treatments in the Adial pipeline. Thank you to William Stilley for joining me on the podcast.
If you enjoy this podcast episode, please subscribe. Also, please visit our practice website at https://drleeds.com and our podcast website: https://therehab.com.